This publication has been discontinued on September 9, 2011.
Abstract
Angina Pectoris - Drug Pipeline Analysis and Market Forecasts to 2016
Summary
GlobalData, the industry analysis specialist, has released a new report on the
Pharmaceutical and Healthcare industry, “Angina Pectoris - Drug
Pipeline Analysis and Market Forecasts to 2016” is an essential source
of information and analysis on the global angina pectoris market. The report
identifies the key trends shaping and driving the global angina pectoris
market, a key segment within the pharma industry. The report also provides
insight on the prevalent competitive landscape and the emerging players
expected to bring significant shift in the market positioning of the existing
market leaders. Most importantly, the report provides valuable insight on the
pipeline products within the global angina pectoris sector.
This report is built using data and information sourced from proprietary
databases, primary and secondary research and in house analysis by
GlobalData’s team of industry experts.
Scope
The scope of the report includes:
- Annualized global angina pectoris
market revenue data from 2001 to 2009, forecast forward 7 years to 2016.
- Geographies covered in this report include the US (United States), the UK
(United Kingdom), Italy, Spain, Germany, France, and Japan.
- Pipeline
analysis data providing a split across different phases, mechanisms of action
being developed and emerging trends. Key classes of mechanism of action
includes gene therapy, combinational therapies, nitric oxide targettors,
beta-1 adrenergic receptor antagonists, stem cell therapy, enzyme inhibitors,
immunologic drugs, coagulation factor Xa inhibitors, adenosine A1 agonists,
anticoagulants and calcium/potassium and sodium channel blockers.
-
Analysis of the current and future market competition in the global angina
pectoris market. The key market players covered are Solvay Pharmaceuticals,
Cardium Therapeutics, Inc., Bayer Healthcare AG., Atherogenics, Inc.,
Cytokinetics, Inc, Arca Biopharma, Inc., Anthera Pharmaceuticals, Inc, Lacer
S.A and Circ Pharma.
- Insightful review of the key industry drivers,
restraints and challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
- Key topics covered include
strategic competitor assessment, market characterization, unmet needs and
implications for future market associated with angina pectoris
Reasons to buy
The report will enhance your decision making capability in a more rapid and
time sensitive manner. It will allow you to:
- Develop and design your
in-licensing and out-licensing strategies through review of pipeline products
and technologies and by identifying companies with the most robust
pipeline.
- Develop business strategies by understanding the trends
shaping and driving the global angina pectoris market.
- Drive revenues
by understanding key trends, innovative products and technologies, market
segments and companies likely to impact the global angina pectoris market in
future.
- Formulate effective sales and marketing strategies by
understanding the competitive landscape and by analyzing the performance of
various competitors.
- Identify emerging players with potentially strong
product portfolio and create effective counter-strategies to gain
competitive advantage.
- Organize your sales and marketing efforts by
identifying the market categories and segments that present maximum
opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global angina pectoris market
landscape? - Identify, understand and capitalize.
Table of Contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2
Angina Pectoris Market: Market Characterization 6
2.1 Overview 6
2.2
Angina Pectoris Market Size 6
2.3 Angina Pectoris Market Forecast and CAGR
6
2.4 Drivers and Barriers for the Angina Pectoris Market 7
2.4.1
Drivers for the Angina Pectoris Market 8
2.4.2 Barriers for the Angina
Pectoris Market 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway
10
3 Angina Pectoris Market: Competitive Assessment 11
3.1 Overview
11
3.2 Strategic Competitor Assessment 11
3.3 Major Therapies and
Product Profiles for the Major Marketed Products in the Angina Pectoris Market
12
3.3.1 Calcium Channel Blockers 12
3.3.2 Nitrates 13
3.3.3
Beta-adrenergic Blocking Agents (Beta Blockers) 14
3.3.4 Angiotensin
Converting Enzyme Inhibitor (ACE inhibitors) 14
3.3.5 Statins 15
3.3.6
Sodium Channel Current Inhibitor 16
3.3.7 Selective If Channel Inhibitor
18
3.3.8 Glycoprotein IIb/IIIa inhibitor 19
3.4 Key Takeaway 25
4
Angina Pectoris Market: Pipeline Assessment 26
4.1 Overview 26
4.2
Strategic Pipeline Assessment 26
4.2.1 Technology Trends Analytic
Framework 26
4.3 Angina Pectoris Therapeutics - Promising Drugs
under Clinical Development 27
4.4 Molecule Profile for Promising Drugs
under Clinical Development 29
4.4.1 Generx (Alferminogene Tadenovec,
Ad5FGF-4) 29
4.4.2 Rivaroxaban (Xarelto, BAY 59-7939) 31
4.4.3
Tedangin (Tedisamil Sesquifumurate, KC-8857, Pulzium) 33
4.4.4 Fasudil
(AT-877) 34
4.4.5 AGI-1067 (Succinobucol) 35
4.4.6 CK-1827452
(Omecamtiv mecarbil, CK-452) 36
4.4.7 RNAPc2 (recombinant nematode
anticoagulant protein c2) 37
4.4.8 A-002 (Varespladib Methyl) 38
4.4.9
LA419
(S-(6-Nitro-oxi-hexahydrofuro[3,2-b]furan-3-1-il)thioacetate])
39
4.5 Angina Pectoris Therapeutics Market - Clinical Pipeline by
Mechanism of Action 40
4.6 Angina Pectoris Pipeline - Pipeline by
Clinical Phases of Development 41
4.6.1 Angina Pectoris Therapeutics
- Phase III Clinical Pipeline 41
4.6.2 Angina Pectoris Therapeutics
- Phase II Clinical Pipeline 42
4.6.3 Angina Pectoris Therapeutics
- Phase I Clinical Pipeline 43
4.6.4 Angina Pectoris Therapeutics
- Preclinical Pipeline 43
4.7 Discontinued / Suspended Drug for
Angina Pectoris 44
4.8 Key Takeaway 45
5 Angina Pectoris Market:
Implications for Future Market Competition 47
6 Angina Pectoris Market:
Future Players in the Angina Pectoris Market 48
6.1 Introduction 48
6.2 Cardium Therapeutics, Inc. 48
6.2.1 Overview 48
6.2.2
Cardiovascular Disease Portfolio 49
6.2.3 Angina Product Portfolio 49
6.3 Bayer Healthcare AG 51
6.3.1 Overview 51
6.3.2 Cardiovascular
Disease Portfolio 52
6.3.3 Angina Product Portfolio 52
6.4 Solvay
Pharmaceuticals 53
6.4.1 Overview 53
6.4.2 Cardiovascular Disease
Portfolio 54
6.4.3 Angina Product Portfolio 54
6.5 Atherogenics, Inc.
55
6.5.1 Overview 55
6.5.2 Cardiovascular Disease Portfolio 56
6.5.3 Angina Product Portfolio 56
6.6 Cytokinetics, Inc. 57
6.6.1
Business Description 57
6.6.2 Cardiovascular Disease Portfolio 58
6.6.3 Angina Product Portfolio 58
6.7 ARCA Biopharma. Inc. 59
6.7.1
Overview 59
6.7.2 Cardiovascular Disease Portfolio 59
6.7.3 Angina
Product Portfolio 59
6.8 Anthera Pharmaceuticals, Inc. 61
6.8.1
Overview 61
6.8.2 Cardiovascular Disease Portfolio 61
6.8.3 Angina
Product Portfolio 61
6.9 Lacer S.A 62
6.9.1 Business Description
62
6.9.2 Cardiovascular Disease Portfolio 62
6.9.3 Angina Product
Portfolio 62
6.10 Circ Pharma 63
6.10.1 Business Description 63
6.10.2 Cardiovascular Disease Portfolio 64
6.10.3 Angina Product Portfolio
64
7 Angina Pectoris Market: Appendix 65
7.1 Market Definitions 65
7.2 Abbreviations 65
7.2.1 Coverage 67
7.2.2 Secondary Research 67
7.2.3 Forecasting 68
7.2.4 Primary Research 70
7.2.5 Expert Panels
Validation 71
7.3 Contact Us 71
7.4 Disclaimer 71
7.5 Sources
71
1.1 List of Tables
Table 1: Global Angina Pectoris Market
Revenue ($bn), 2001-2009 7
Table 2: Global Angina Pectoris Market
Revenue ($bn), 2009-2016 7
Table 3: Major Marketed Products Comparison
in the Angina Pectoris Market, January 2010 24
Table 4: Angina Pectoris
Therapeutics - Most Promising Drugs Under Clinical Development, 2010
27
Table 5: Angina Pectoris Therapeutics - Phase III Clinical
Pipeline, 2010 41
Table 6: Angina Pectoris Therapeutics - Phase
II Clinical Pipeline, 2010 42
Table 7: Angina Pectoris Therapeutics
- Phase I Clinical Pipeline, 2010 43
Table 8: Angina Pectoris
Therapeutics - Preclinical Pipeline, 2010 43
Table 9: List of
Discontinued Drugs for Angina Pectoris, 2010 44
Table 10: Cardium
Therapeutics, Inc. -Cardiovascular Pipeline Products, 2010 49
Table
11: Bayer Healthcare AG -Cardiovascular Pipeline Products, 2010 52
Table 12: Solvay Pharmaceuticals -Cardiovascular Pipeline Products,
2010 54
Table 13: Atherogenics, Inc. Laboratories-Cardiovascular
Pipeline Products, 2010 56
Table 14: Cytokinetics,
Inc.-Cardiovascular Pipeline Products, 2010 58
Table 15: Arca
Biopharma, Inc.-Cardiovascular Pipeline Products, 2010 59
Table 16:
Anthera Pharmaceuticals, Inc. Cardiovascular Pipeline Products, 2010 61
Table 17: Lacer S.A Laboratories-Cardiovascular Pipeline Products, 2010
62
Table 18: Circ Pharma-Cardiovascular Pipeline Products, 2010
64
1.2 List of Figures
Figure 1: Global Angina Pectoris Market
Revenue ($m), 2001-2009 6
Figure 2: Global Angina Pectoris Market
Revenue ($m), 2009-2016 7
Figure 3: Opportunity and Unmet Need in the
Angina Disease Market, 2010 9
Figure 4: Strategic Competitor Assessment
of the Major Marketed Products in Angina Pectoris, 2010 12
Figure 5:
Technology Trends Analytic Framework of the Angina Pectoris Pipeline, 2010
26
Figure 6: Technology Trends Analytic Framework of the Angina
Pectoris Pipeline - Description, 2010 27
Figure 7: Angina
Pectoris Therapeutics Market - Clinical Pipeline by Mechanism of Action,
2010 40
Figure 8: Angina Pectoris Pipeline by Phase of Clinical
Development, 2010 41
Figure 9: Implications for Future Market
Competition in the Angina Pectoris Market, 2010 47
Figure 10: Angina
Pectoris Therapeutics Market - Clinical Pipeline by Company, 2010 48
Figure 11: GlobalData Methodology, 2010 67
Figure 12: GlobalData Market
Forecasting Model, 2010 70
